Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Pseudoepitheliomatous Hyperplasia Associated with Bisphosphonate-related Osteonecrosis of the Jaw

JOZEF ZUSTIN, DENNIS RESKE, TOMISLAV A. ZRNC, MAX HEILAND, HANNA A. SCHEUER, ALEXANDRE T. ASSAF and REINHARD E. FRIEDRICH
In Vivo January 2014, 28 (1) 125-131;
JOZEF ZUSTIN
1Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.zustin{at}uke.uni-hamburg.de
DENNIS RESKE
1Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMISLAV A. ZRNC
2Department of Oral- and Maxillofacial Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAX HEILAND
2Department of Oral- and Maxillofacial Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANNA A. SCHEUER
3Department of Orthodontics, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDRE T. ASSAF
2Department of Oral- and Maxillofacial Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
REINHARD E. FRIEDRICH
2Department of Oral- and Maxillofacial Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-characterized oral complication of systemic therapy with bisphosphonates. Pseudoepitheliomatous hyperplasia was observed in some of the lesions. Because podoplanin expression has been linked to malignant lesions of the oral mucosa, we aimed to investigate podoplanin expression in the pseudoepitheliomatous hyperplasia. We analyzed archival paraffin- and plastic-embedded specimens from BRONJ using both conventional and immunohistochemical (AE1/AE3, D2-40) staining methods. Eleven out of seventeen BRONJ cases showed pseudoepitheliomatous hyperplasia. All these cases were positive for AE1/AE3 and pseudoepitheliomatous hyperplasia displayed a strong basal and parabasal reaction against podoplanin. The podoplanin expression in pseudoepitheliomatous hyperplasia in BRONJ specimens should not be considered a sign of malignancy. We discuss the current and possible future roles of surgical pathologists in diagnosing morphological changes associated with the development and therapy of BRONJ lesions.

  • Pseudoetheliomatous hyperplasia
  • BRONJ
  • bisphosphonate
  • podoplanin
  • D2-40

Ten years ago, Robert E. Marx first described a series of patients suffering from exposed and non-healing jaw bones after treatment with bisphosphonates, a side-effect subsequently confirmed by several other studies and known as bisphosphonate-associated osteonecrosis of the jaw (BRONJ) (1). Although several hypotheses regarding the pathogenesis of BRONJ have been proposed, the exact mechanism of bisphosphonate-associated osteonecrosis has not yet been determined. According to the definition of BRONJ established by the American Association of Oral and Maxillofacial Surgeons (AAOMS), patients may be considered to have BRONJ if each of the following three characteristics is present: (1) Current or previous treatment with a bisphosphonate; (2) exposed, necrotic bone in the maxillofacial region that has persisted for more than eight weeks; and (3) no history of radiation therapy to the jaws (2). Even though initial stages of BRONJ do not require intervention other than periodic antibiotic oral rinses, sometimes in combination with systemic antibiotic therapy, the large burden of necrotic bone results in extra-oral fistulization (3, 4), pathological fracture or progressive development of an oral-maxillary sinus fistula which require for aggressive surgical management.

Microscopically, advanced lesions of BRONJ are characterized by findings of bacteria (4-9), necrotic bone sequestra, purulent inflammation, and granulation tissue with numerous osteoclasts (10-13) associated with sclerotic changes of remaining viable bone tissue (10, 14). Furthermore, a pseudoepitheliomatous hyperplasia (4) has been observed in bisphosphonate osteonecrosis of the jaw (BRONJ) lesions.

Podoplanin (synonyms: T1α, aggrus, human gp36) is a type-1 transmembrane sialomucin-like glycoprotein consisting of 162 amino acids, nine of which are form the intracellular domain (15). The extracellular domain of podoplanin is rich in Ser and Thr and contains multiple potential O-glycosylation sites (16). As podoplanin is expressed in lymphatic but not in blood vessel endothelium, it has been widely used as a specific marker for lymphatic endothelial cells and lymphangiogenesis (17-19). Recent studies, however, have described podoplanin expression in various normal and neoplastic tissues. Even though podoplanin expression has been reported in both neoplastic (20) and inflammatory altered oral mucosa (21) as well as in odontogenic lesions (22-26), normal oral mucosa does not exhibit podoplanin expression with the exception of the submucosal lymph vessels (21).

Because podoplanin expression has previously been reported in inflamed gingival epithelium (21), we hypothesized that podoplanin expression is enhanced in pseudoepitheliomatous hyperplasia in BRONJ. In the present study, we therefore investigated (a) the occurrence of pseudoepithelial hyperplasia in our cases of partial jaw bone resection specimens with BRONJ, and (b) the expression of podoplanin in cases showing pseudoepithelial hyperplasia.

Materials and Methods

Case selection. We retrospectively investigated morphological changes in cases of BRONJ with partial jaw bone resection treated at the University Medical Center Hamburg-Eppendorf, Germany from April 2011 to April 2013. Each patient was evaluated clinically and additional imaging examinations were performed. All patients fulfilled the AAOSM criteria of BRONJ (2).

Immunohistochemical staining and evaluation. The archival tissues were paraffin- and methyl-methacrylate-embedded bone specimens from each case, which were stained with Goldner trichrome, periodic acid-Schiff, Giemsa and haematoxylin and eosin staining methods. All slides were reviewed, and representative sections from the formalin-fixed, paraffin-embedded tissue blocks were examined using automated immunohistochemistry systems. The freshly-cut sections were loaded into a PT Link module (Dako, Glostrup Denmark) and subjected to an antigen retrieval/de-waxing protocol with the Dako EnVision FLEX Target Retrieval Solution, at high pH, and then transferred to the Dako Autostainer Link 48 instrument. Immunostaining was performed using the primary antibodies AE1/AE3 (Dako IR053, Glostrup, Denmark), and D2-40 (Dako IR072, Glostrup, Denmark), and the Dako EnVision Flex detection system. Microscopic analyses were performed using a Zeiss microscope (Axiophot, Carl Zeiss, Jena, Germany) and representative microphotographs were performed using a digital camera (AxioCam MRc, Carl Zeiss, Jena, Germany), and AxioVision Rel.4.8 imaging software (Carl Zeiss, Jena, Germany). Both immunohistochemical staining intensity (scored as negative, weak, moderate or strong) and distribution (basal, parabasal, luminal) were recorded along with the relative proportion of immunohistochemically-positive cells.

Results

Study cohort demographics. The study cohort consisted of 17 consecutive patients who underwent a partial jaw resection for BRONJ at the University Medical Center Hamburg-Eppendorf, Germany from April 2011 to April 2013. Demographic and clinical data are summarized in Table I.

Morphological characteristics of BRONJ lesions. All specimens showed a similar layering structure in the BRONJ lesions. Clinical radiographs and computed tomography (Figure 1A) showed an osteolytic jaw bone lesion with central sequester. The gross analysis of the resection specimens showed periostal bone formation (Figure 1B) and central necrotic tissues. The specimens were verticaly-lamellated and further analyzed radiographically and macroscopically. The specimens displayed jaw bone with new periostal bone formation and a central osteolytic lesion reaching the oral surface. On slab radiographs, osteolysis was seen to reach both the cortical bone and the mineralized periostal bone (Figure 1C) in the majority of our cases. The osteolytic bone defects contained of soft tissue with scattered fragments of necrotic bone sequestrae. Macroscopically (Figure 1D), the superficial necrotic areas appeared red to brown colored, depending on the degree of formalin fixation of the tissues. The remaining cortical bone appeared somewhat more yellowish when compared to intraosseous sclerotic spongiosa and newly-periostal formed bone tissue. None of the cases from our study cohort showed extraoral fistulization.

Microscopically, the superficial areas on the BRONJ lesions contained necrotic bone colonized by diverse bacteria (Figure 2A) including characteristic colonies of Actinomyces (Figure 2B). The latter was found both in-between necrotic trabeculae and also attached to the trabecular surface. Six out of seventeen cases showed areas of de-mineralization of the necrotic bone sequester, partially superficial (Figure 2C), but also deeper in the bone matrix (Figure 2D). Some necrotic bone particles were embedded in the inflamed granulation tissue and were closely-associated with the pseudoepitheliomatous hyperplasia (Figure 2E). Other bone lesions showed continuous superficial pseudoepitheliomatous hyperplasia with extensions into the deeper layers and massive purulent exudate (Figure 2F). Some of the lesions displayed deep viable bone tissue covered by inflamed granulation tissue lined-up with pseudoepithelial hyperplasia (Figure 2G). Numerous osteoclasts were apparent within the granulation tissue and on the border of the viable bone remnant as well (Figure 2H). The majority of the resection specimens showed distinct new periosteal bone formation (Figure 2I).

Pseudoepitheliomatous hyperplasia and podoplanin expression in clinical samples. Pseudoepitheliomatous hyperplasia was observed in 11 out of 17 BRONJ cases (Table I) in our study cohort and consisted of irregular squamous epithelial proliferation (Figure 3A) associated with inflammation and formation of granulation tissue. The pseudoepithelial hyperplasia was one to several cell layers-thick and located both at the bone surface with extension into the granulation tissue and on the inner surface of the BRONJ lesion. All cases showed positive immunohistochemical reaction against the pancytokeratin marker AE1/AE3 (Figure 3B) and positive reaction of basal and parabasal keratinocytes with podoplanin (Figure 3C), as well. Even though mitoses were found within the pseudoepithelial hyperplasia, no dysplastic changes in the epithelial cells were observed.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Bisphosphonate-related osteonecrosis of the jaw. Characteristics of the study cohort.

Discussion

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-characterized oral complication that affects approximately 0.94%-10% of patients with cancer who are treated with intravenous bisphosphonates (27, 28). It is rare in patients taking oral bisphosphonates for osteoporosis. In the vast majority of cases, BRONJ is characterized by exposed necrotic bone in the oral cavity that develops spontaneously or following dental extractions or other surgical procedures (29); however, cases with non-exposed osteonecrosis have also been reported (30, 31).

Our study confirmed the finding of a characteristic layering structure of BRONJ lesions (4, 10) with superficial necrotic bone tissue colonized by bacteria, deeper inflamed granulation tissue and sclerotic bone and focal new periostal bone formation. Even though most researchers (3-5, 11, 12, 14, 32, 33) investigated decalcified bone tissues taken from BRONJ lesions, few studies of non-decalcified bone biopsies from BRONJ lesions have already been reported (11, 34, 35). We also chose an undecalcified method of processing bone biopsies, because it enabled for light microscopic analysis of both non-mineralized and mineralized bone matrix. Interestingly, we observed de-mineralization of necrotic bone tissue in BRONJ lesions that did not appear to be linked with osteoclastic bone resorption. Areas with newly-formed osteoid rimmed by osteoblasts and mineralized new periostal bone formation were also well-demonstrated using undecalcified bone specimens. In contrast to Bedogni et al. who suggested osteomalacia in patients with BRONJ (35), we observed reactive new periosteal bone formation and maturing callus tissue in the jaw bone. However, further research on local and systemic bone metabolism in BRONJ patients is necessary to explain for the possible causal relationship between adverse effects of bisphosphonate medication and osteomalacia.

Similarly to Hansen et al. (4, 32), we observed pseudoepithelial hyperplasia in a substantial proportion of BRONJ cases and can confirm their suggestion that it is a relatively common feature reflecting the oral mucosal disruption. As our study cohort did not contain cases with extraoral fistulization, we suggest that the pseudoepithelial hyperplasia either arose from remaining periodontal squamous epithelium or represents epithelial proliferation of the neighboring gingival epithelium rather than ingrowths of the squamous epithelium of the skin. We hypothesize that this finding represents an attempt of the oral tissues to demarcate the necrotic inflamed tissues and to subsequently re-epithelialize the bottom of the ulcerated BRONJ lesions and thus restore mucosal barrier function. This suggestion was further supported by the finding of podoplanin expression by basal and parabasal keratinocytes, analogous to the staining pattern reported in chronic inflamed gingival epithelium (21).

In the current study, we observed podoplanin expression in the basal and parabasal epithelial layers in pseudopeitheliomatous hyperplasia associated with BRONJ. Even though podoplanin has been linked to oral squamous cancer (20, 36-42), the pattern of its expression in pseudoepitheliomatous hyperplasia associated with BRONJ seems analogous to other inflammatory oral lesions (21, 24) and should, thus, not be considered a sign of malignancy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

BRONJ, gross findings. (A) Clinical CT showed an osteolytic jaw bone lesion with central sequester. (B) The surface of the jaw bone was covered with new periosteal bone formation. (C) Slab radiograph revealed a central sequester, and the remainings of cortical bone with concentric lamellated new periosteal bone formations. (D) Macroscopically, brownish necrotic tissues were apparent.

Based on our results it can be stated that histopathological diagnosis of BRONJ is unproblematic as long as surgical pathologists obtain relevant clinical data and larger excision specimens for their analysis. However, it can be quite problematic to confirm the clinical diagnosis in cases with only small or fragmented biopsy specimens taken from the border of the lesion, which might contain only viable inflamed granulation tissue without bone sequester. Altogether, the current roles of the surgical pathologist in diagnosing BRONJ are firstly to confirm the presence of BRONJ, and secondly to exclude a malignancy. Even though some authors have concluded that BRONJ is quite similar to jaw osteonecrosis associated with radiotherapy treatment (34), other researchers observed some substantial differences between the two lesions; of particular interest were the vessel obliteration (12) and patchy pattern of osteonecrosis (4) in BRONJ. Although malignant tumors have only rarely been observed in association with BRONJ (43-46), malignancy must also be excluded by histopathological analysis. In our study cohort, we did not observe malignant tumor infiltrates in BRONJ lesions.

With further development of surgical methods, one possible future role of the surgical pathologist might be validation of minimal but efficient curative surgery performed in BRONJ cases. Indeed, intraoperative visualization of viable versus necrotic bone areas by means of fluorescence-guided bone resection following doxycycline labeling of newly-formed bone has recently been shown to be useful in detecting the borders of BRONJ lesions (47). This and/or other novel surgical techniques might help define the best possible time for and extent of surgery in BRONJ cases in the future.

Conclusion

We demonstrated podoplanin expression in non-neoplastic pseudoepitheliomatous hyperplasia associated with BRONJ lesions. We discussed the current and possible future roles of surgical pathologists in diagnosing morphological changes associated with the development and therapy of BRONJ lesions.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

BRONJ, histopathological findings. (A) In between the osteosclerotic bone trabeculae, granulation tissue and bacterial colonies were apparent under low-power microscopy (periodic acid-Schiff; original magnification: ×50). (B) On the surface necrotic bone tissue, Actinomyces bacteria and neutrophils were seen under higher-power microscopy (periodic acid-Schiff, ×400). Areas of de-mineralized bone matrix were seen both (C) superficially and (D) within the deeper bone regions (C/D: Goldner trichrome, ×400). (E) Some BRONJ lesions showed fragments of necrotic bone sequester embedded in inflamed granulation tissue and pseudoepitheliomatous hyperplasia. (F) Similarly, pseudoepitheliomatous hyperplasia covering the bottom of BRONJ lesions was in some cases covered by purulent exudate. (G) Viable bone in several BRONJ lesions with desquamated bone sequester were covered by granulation tissue showing hyperemia and superficial seam of pseudoepitheliomatous hyperplasia (E/F/G: Goldner trichrome, ×100). (H) Deeper viable bone tissue showed often numerous osteoclasts within the proliferated granulation tissue (Giemsa, ×200). (I) The majority of the resection specimens showed distinct new periosteal bone formation (Goldner trichrome, ×50).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Pseudoepitheliomatous hyperplasia. (A) Pseudoepitheliomatous hyperplasia was apparent within the inflamed granulation tissue (Goldner trichrome, ×100). (B) Epithelial nature of the proliferated epithelium was highlighted using immunohistochemistry (AE1/AE3, ×100). (C) Podoplanin expression was seen in basal and parabasal layers (D2-40, ×100).

Footnotes

  • ↵# These Authors contributed equally to this study

  • ↵× These Authors share senior authorship.

  • Conflicts of Interest

    We declare that we have no conflicts of interest (either financial or personal) in regard to this study. This work has not been published or presented (oral, print or online) elsewhere in whole, nor in part.

  • Received October 24, 2013.
  • Revision received November 9, 2013.
  • Accepted November 12, 2013.
  • Copyright © 2014 The Author(s). Published by the International Institute of Anticancer Research.

References

  1. ↵
    1. Marx RE
    : Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117, 2003.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ruggiero SL,
    2. Dodson TB,
    3. Assael LA,
    4. Landesberg R,
    5. Marx RE,
    6. Mehrotra B,
    7. American Association of Oral and Maxillofacial Surgeons
    : American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 67: 2-12, 2009.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bedogni A,
    2. Blandamura S,
    3. Lokmic Z,
    4. Palumbo C,
    5. Ragazzo M,
    6. Ferrari F,
    7. Tregnaghi A,
    8. Pietrogrande F,
    9. Procopio O,
    10. Saia G,
    11. Ferretti M,
    12. Bedogni G,
    13. Chiarini L,
    14. Ferronato G,
    15. Ninfo V,
    16. Lo Russo L,
    17. Lo Muzio L,
    18. Nocini PF
    : Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105: 358-364, 2008.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Hansen T,
    2. Kunkel M,
    3. Springer E,
    4. Walter C,
    5. Weber A,
    6. Siegel E,
    7. Kirkpatrick CJ
    : Actinomycosis of the jaws – histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451: 1009-1017, 2007.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Schipmann S,
    2. Metzler P,
    3. Rossle M,
    4. Zemann W,
    5. von Jackowski J,
    6. Obwegeser JA,
    7. Gratz KW,
    8. Jacobsen C
    : Osteopathology associated with bone resorption inhibitors - which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature. J Oral Pathol Med 42: 587-593, 2013.
    OpenUrlPubMed
    1. Kaplan I,
    2. Anavi K,
    3. Anavi Y,
    4. Calderon S,
    5. Schwartz-Arad D,
    6. Teicher S,
    7. Hirshberg A
    : The clinical spectrum of Actinomyces-associated lesions of the oral mucosa and jawbones: correlations with histomorphometric analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108: 738-746, 2009.
    OpenUrlPubMed
    1. Bisdas S,
    2. Chambron Pinho N,
    3. Smolarz A,
    4. Sader R,
    5. Vogl TJ,
    6. Mack MG
    : Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63: 71-77, 2008.
    OpenUrlCrossRefPubMed
    1. Lugassy G,
    2. Shaham R,
    3. Nemets A,
    4. Ben-Dor D,
    5. Nahlieli O
    : Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 117: 440-441, 2004.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sedghizadeh PP,
    2. Kumar SK,
    3. Gorur A,
    4. Schaudinn C,
    5. Shuler CF,
    6. Costerton JW
    : Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 140: 1259-1265, 2009.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Cho YA,
    2. Yoon HJ,
    3. Lee JI,
    4. Hong SP,
    5. Hong SD
    : Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies. Oral Surg Oral Med Oral Pathol Oral Radiol 114: 785-791, 2012.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Favia G,
    2. Pilolli GP,
    3. Maiorano E
    : Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406-413, 2009.
    OpenUrlPubMed
  9. ↵
    1. Hansen T,
    2. Kunkel M,
    3. Weber A,
    4. James Kirkpatrick C
    : Osteonecrosis of the jaws in patients treated with bisphosphonates – histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160, 2006.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bittner T,
    2. Lorbeer N,
    3. Reuther T,
    4. Bohm H,
    5. Kubler AC,
    6. Muller-Richter UD,
    7. American Association of Oral and Maxillofacial Surgeons
    : Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: a case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 113: 41-47, 2012.
    OpenUrlPubMed
  11. ↵
    1. Dodson TB,
    2. Raje NS,
    3. Caruso PA,
    4. Rosenberg AE
    : Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 358: 1283-1291, 2008.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Schacht V,
    2. Ramirez MI,
    3. Hong YK,
    4. Hirakawa S,
    5. Feng D,
    6. Harvey N,
    7. Williams M,
    8. Dvorak AM,
    9. Dvorak HF,
    10. Oliver G,
    11. Detmar M
    : T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22: 3546-3556, 2003.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Kaneko MK,
    2. Kato Y,
    3. Kameyama A,
    4. Ito H,
    5. Kuno A,
    6. Hirabayashi J,
    7. Kubota T,
    8. Amano K,
    9. Chiba Y,
    10. Hasegawa Y,
    11. Sasagawa I,
    12. Mishima K,
    13. Narimatsu H
    : Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett 581: 331-336, 2007.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kahn HJ,
    2. Bailey D,
    3. Marks A
    : Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15: 434-440, 2002.
    OpenUrlCrossRefPubMed
    1. Kahn HJ,
    2. Marks A
    : A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 82: 1255-1257, 2002.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hirakawa S,
    2. Hong YK,
    3. Harvey N,
    4. Schacht V,
    5. Matsuda K,
    6. Libermann T,
    7. Detmar M
    : Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 162: 575-586, 2003.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Inoue H,
    2. Miyazaki Y,
    3. Kikuchi K,
    4. Yoshida N,
    5. Ide F,
    6. Ohmori Y,
    7. Tomomura A,
    8. Sakashita H,
    9. Kusama K
    : Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol 33: 183-194, 2012.
    OpenUrlPubMed
  17. ↵
    1. Miyazaki Y,
    2. Okamoto E,
    3. Gonzalez-Alva P,
    4. Hayashi J,
    5. Ishige T,
    6. Kikuchi K,
    7. Nemoto N,
    8. Shin K,
    9. Sakashita H,
    10. Ochiai K,
    11. Kusama K
    : The significance of podoplanin expression in human inflamed gingiva. J Oral Sci 51: 283-287, 2009.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Friedrich RE,
    2. Scheuer HA,
    3. Zustin J
    : Expression of podoplanin in nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumours. Anticancer Res 32: 2125-2127, 2012.
    OpenUrlAbstract/FREE Full Text
    1. Assaf AT,
    2. Heiland M,
    3. Blessmann M,
    4. Friedrich RE,
    5. Zustin J,
    6. Al-Dam A
    : Extensive sublingual epidermoid cyst – diagnosis by immunohistological analysis and proof by podoplanin. In Vivo 26: 323-326, 2012.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Zustin J,
    2. Scheuer HA,
    3. Friedrich RE
    : Podoplanin expression in human tooth germ tissues and cystic odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 39: 115-120, 2010.
    OpenUrlPubMed
    1. Gonzalez-Alva P,
    2. Tanaka A,
    3. Oku Y,
    4. Miyazaki Y,
    5. Okamoto E,
    6. Fujinami M,
    7. Yoshida N,
    8. Kikuchi K,
    9. Ide F,
    10. Sakashita H,
    11. Kusama K
    : Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med 39: 103-109, 2010.
    OpenUrlPubMed
  20. ↵
    1. Okamoto E,
    2. Kikuchi K,
    3. Miyazaki Y,
    4. Gonzalez-Alva P,
    5. Oku Y,
    6. Tanaka A,
    7. Yoshida N,
    8. Fujinami M,
    9. Ide F,
    10. Sakashita H,
    11. Kusama K
    : Significance of podoplanin expression in keratocystic odontogenic tumor. J Oral Pathol Med 39: 110-114, 2010.
    OpenUrlPubMed
  21. ↵
    1. Bamias A,
    2. Kastritis E,
    3. Bamia C,
    4. Moulopoulos LA,
    5. Melakopoulos I,
    6. Bozas G,
    7. Koutsoukou V,
    8. Gika D,
    9. Anagnostopoulos A,
    10. Papadimitriou C,
    11. Terpos E,
    12. Dimopoulos MA
    : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587, 2005.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Stumpe MR,
    2. Chandra RK,
    3. Yunus F,
    4. Samant S
    : Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head Neck 31: 202-206, 2009.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ruggiero SL,
    2. Mehrotra B,
    3. Rosenberg TJ,
    4. Engroff SL
    : Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534, 2004.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Fedele S,
    2. Porter SR,
    3. D'Aiuto F,
    4. Aljohani S,
    5. Vescovi P,
    6. Manfredi M,
    7. Arduino PG,
    8. Broccoletti R,
    9. Musciotto A,
    10. Di Fede O,
    11. Lazarovici TS,
    12. Campisi G,
    13. Yarom N
    : Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123: 1060-1064, 2010.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Yarom N,
    2. Fedele S,
    3. Lazarovici TS,
    4. Elad S
    : Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 68: 705, 2010.
    OpenUrlPubMed
  26. ↵
    1. Hansen T,
    2. Kirkpatrick CJ,
    3. Walter C,
    4. Kunkel M
    : Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis – a paradoxical observation? Virchows Arch 449: 448-454, 2006.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Marx RE,
    2. Tursun R
    : Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg 41: 283-289, 2012.
    OpenUrlPubMed
  28. ↵
    1. Carmagnola D,
    2. Canciani E,
    3. Sozzi D,
    4. Biglioli F,
    5. Moneghini L,
    6. Dellavia C
    : Histological findings on jaw osteonecrosis associated with bisphosphonates (BONJ) or with radiotherapy (ORN) in humans. Acta Odontol Scand 7: 1410-1417, 2013.
    OpenUrl
  29. ↵
    1. Bedogni A,
    2. Saia G,
    3. Bettini G,
    4. Tronchet A,
    5. Totola A,
    6. Bedogni G,
    7. Tregnago P,
    8. Valenti MT,
    9. Bertoldo F,
    10. Ferronato G,
    11. Nocini PF,
    12. Blandamura S,
    13. Dalle Carbonare L
    : Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws? Oncologist 17: 1114-1119, 2012.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Tsuneki M,
    2. Maruyama S,
    3. Yamazaki M,
    4. Xu B,
    5. Essa A,
    6. Abe T,
    7. Babkair H,
    8. Cheng J,
    9. Yamamoto T,
    10. Saku T
    : Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells. Biochem Biophys Res Commun 434: 124-130, 2013.
    OpenUrlPubMed
    1. Tsuneki M,
    2. Yamazaki M,
    3. Maruyama S,
    4. Cheng J,
    5. Saku T
    : Podoplanin-mediated cell adhesion through extracellular matrix in oral squamous cell carcinoma. Lab Invest 93: 921-932, 2013.
    OpenUrlCrossRefPubMed
    1. de Vicente JC,
    2. Rodrigo JP,
    3. Rodriguez-Santamarta T,
    4. Lequerica-Fernandez P,
    5. Allonca E,
    6. Garcia-Pedrero JM
    : Podoplanin expression in oral leukoplakia: tumorigenic role. Oral Oncol 49: 598-603, 2013.
    OpenUrlCrossRefPubMed
    1. Bartuli FN,
    2. Luciani F,
    3. Caddeo F,
    4. Compagni S,
    5. Piva P,
    6. Ottria L,
    7. Arcuri C
    : Podoplanin in the development and progression of oral cavity cancer: a preliminary study. Oral Implantol (Rome) 5: 33-41, 2012.
    OpenUrlPubMed
    1. Inoue H,
    2. Miyazaki Y,
    3. Kikuchi K,
    4. Yoshida N,
    5. Ide F,
    6. Ohmori Y,
    7. Tomomura A,
    8. Sakashita H,
    9. Kusama K
    : Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. J Oral Sci 54: 241-250, 2012.
    OpenUrlPubMed
    1. Kreppel M,
    2. Kreppel B,
    3. Drebber U,
    4. Wedemayer I,
    5. Rothamel D,
    6. Zoller JE,
    7. Scheer M
    : Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis 18: 692-699, 2012.
    OpenUrlPubMed
  31. ↵
    1. Kawaguchi H,
    2. El-Naggar AK,
    3. Papadimitrakopoulou V,
    4. Ren H,
    5. Fan YH,
    6. Feng L,
    7. Lee JJ,
    8. Kim E,
    9. Hong WK,
    10. Lippman SM,
    11. Mao L
    : Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26: 354-360, 2008.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Otto S,
    2. Schuler K,
    3. Ihrler S,
    4. Ehrenfeld M,
    5. Mast G
    : Osteonecrosis or metastases of the jaw or both? Case report and review of the literature. J Oral Maxillofac Surg 68: 1185-1188, 2010.
    OpenUrlPubMed
    1. Carlson ER,
    2. Fleisher KE,
    3. Ruggiero SL
    : Metastatic Cancer Identified in Osteonecrosis Specimens of the Jaws in Patients Receiving Intravenous Bisphosphonate Medications. J Oral Maxillofac Surg 2013.
    1. Bedogni A,
    2. Saia G,
    3. Ragazzo M,
    4. Bettini G,
    5. Capelli P,
    6. D'Alessandro E,
    7. Nocini PF,
    8. Lo Russo L,
    9. Lo Muzio L,
    10. Blandamura S
    : Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone 41: 942-945, 2007.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Frei M,
    2. Bornstein MM,
    3. Schaller B,
    4. Reichart PA,
    5. Weimann R,
    6. Iizuka T
    : Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. J Oral Maxillofac Surg 68: 863-867, 2010.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Assaf AT,
    2. Zrnc TA,
    3. Riecke B,
    4. Wikner J,
    5. Zustin J,
    6. Friedrich RE,
    7. Heiland M,
    8. Smeets R,
    9. Grobe A
    : Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Craniomaxillofac Surg 2013.
PreviousNext
Back to top

In this issue

In Vivo
Vol. 28, Issue 1
January-February 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pseudoepitheliomatous Hyperplasia Associated with Bisphosphonate-related Osteonecrosis of the Jaw
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Pseudoepitheliomatous Hyperplasia Associated with Bisphosphonate-related Osteonecrosis of the Jaw
JOZEF ZUSTIN, DENNIS RESKE, TOMISLAV A. ZRNC, MAX HEILAND, HANNA A. SCHEUER, ALEXANDRE T. ASSAF, REINHARD E. FRIEDRICH
In Vivo Jan 2014, 28 (1) 125-131;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Pseudoepitheliomatous Hyperplasia Associated with Bisphosphonate-related Osteonecrosis of the Jaw
JOZEF ZUSTIN, DENNIS RESKE, TOMISLAV A. ZRNC, MAX HEILAND, HANNA A. SCHEUER, ALEXANDRE T. ASSAF, REINHARD E. FRIEDRICH
In Vivo Jan 2014, 28 (1) 125-131;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using equilibrium competing inert hydroxymethylene diphosphonate
  • Radiological and Histopathological Features of Internal Tooth Resorption
  • Google Scholar

More in this TOC Section

  • Signal Detection Analysis of Hypnotic-induced Respiratory Depression
  • Development and Validation of an EHR-based Algorithm for Identifying Pneumocystis jirovecii Pneumonia
  • Safety and Efficacy of SOX Therapy After Preoperative Chemoradiotherapy for Advanced Lower Rectal Cancer: A Phase I Study
Show more Clinical Studies

Keywords

  • Pseudoetheliomatous hyperplasia
  • BRONJ
  • bisphosphonate
  • Podoplanin
  • D2-40
In Vivo

© 2026 In Vivo

Powered by HighWire